Evidence map›Paper›PMID 38075390›Full record

ArticleCase reports in oncology

Controlling Major Portal Vein Invasion Progression during Lenvatinib Treatment by Carbon-Ion Radiotherapy in Patients with Advanced Hepatocellular Carcinoma.

Ryoi Yoshida, Keisuke Koroki, Hirokazu Makishima, Sadahisa Ogasawara, Takamasa Ishino, Keita Ogawa, Miyuki Nakagawa, Kisako Fujiwara, Hidemi Unozawa, Terunao Iwanaga and 21 more

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Case reports in oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 54% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors at 2 institutions in 1 country.

Ryoi YoshidaDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Keisuke KorokiDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Hirokazu MakishimaNational Institutes for Quantum and Radiological Science and Technology QST Hospital, Chiba, Japan.
Sadahisa OgasawaraDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Takamasa IshinoDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Keita OgawaDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Miyuki NakagawaDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Kisako FujiwaraDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Hidemi UnozawaDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Terunao IwanagaDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Naoto FujitaDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Takafumi SakumaDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Hiroaki KanzakiDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Kazufumi KobayashiDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Naoya KanogawaDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Soichiro KiyonoDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Masato NakamuraDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Takayuki KondoDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Tomoko SaitoDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Ryo NakagawaDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Eiichiro SuzukiDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Yoshihiko OokaDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Shingo NakamotoDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Akinobu TawadaDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Tetsuhiro ChibaDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Makoto AraiDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Takashi KanekoNational Institutes for Quantum and Radiological Science and Technology QST Hospital, Chiba, Japan.
Masaru WakatsukiNational Institutes for Quantum and Radiological Science and Technology QST Hospital, Chiba, Japan.
Jun KatoDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Hiroshi TsujiNational Institutes for Quantum and Radiological Science and Technology QST Hospital, Chiba, Japan.
Naoya KatoDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Chiba University · JPNational Institutes for Quantum Science and Technology · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Macrovascular invasion (MVI), including portal vein tumor thrombosis (PVTT), is strongly associated with poor prognosis in patients with hepatocellular carcinoma (HCC). While recommended standard treatment for patients with advanced HCC is systemic therapy, various treatment approaches, including resection, transarterial chemoembolization, and radiation, have been empirically suggested to improve prognosis by eliminating or controlling MVI. Herein, we report our experience of a case with advanced HCC where MVI was controlled by carbon-ion radiotherapy (CIRT) while on systemic therapy, resulting in a prolonged survival. A female patient with HCC in her early 60s had multiple intrahepatic lesions (maximum 60 mm in diameter) with PVTT. The PVTT of this patient had reached the main trunk of the portal vein despite the use of lenvatinib. The other intrahepatic lesions of the patient, except PVTT, had been controlled by lenvatinib. Therefore, hoping to control PVTT, we attempted CIRT. The patient resumed lenvatinib therapy after the irradiation. During lenvatinib re-treatment, no evident progression of PVTT was observed in the patient.

Indexed as

Carbon-ion radiotherapyHepatocellular carcinomaMacrovascular invasion

Identifiers

PMID38075390
PMCPMC10701105
OpenAlexW3186169903

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.